Search

Displaying results 5631 - 5640 of 7479 in total
  1. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    Dichloroacetic acid, often abbreviated DCA, is an acid analogue of acetic acid in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms.

  2. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer

  3. Drug

    Sulfadimethoxine

    go.drugbank.com/drugs/DB06150
    ApprovedVet approvedWithdrawn

    It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.

  4. Drug

    Rosemary

    go.drugbank.com/drugs/DB14272
    Investigational

    It is not an approved drug.

  5. Drug

    RC118

    go.drugbank.com/drugs/DB18428
    Investigational

    RC118 is an antibody-drug conjugate that consists of a recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE.

  6. Drug

    Domofenogene zalfaparvovec

    go.drugbank.com/drugs/DB16810
    Investigational

    Domofenogene zalfaparvovec, formerly known as BMN-307, is an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy developed by BioMarin Pharmaceutical.

  7. Drug

    AT-GTX-502

    go.drugbank.com/drugs/DB17001
    Experimental

    AT-GTX-502 is an experimental, one-time gene therapy that uses AAV9 to deliver a functional copy of CLN3.

  8. Drug

    ATX-F8-117

    go.drugbank.com/drugs/DB17712
    Experimental

    ATX-F8-117 is an investigational peptide derived from Factor VIII. Developed by Apitope, it is being investigated for the treatment of hemophilia A.[L46163]

  9. Drug

    BHV-5000

    go.drugbank.com/drugs/DB17817
    Experimental

    BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is [lanicemine].[L46446]

  10. Drug

    Brazikumab

    go.drugbank.com/drugs/DB16115
    Investigational

    Brazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).